These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Oct 16, 2013Agenus to Report Third Quarter 2013 Financial Results on October 24, 2013; Conference Call to Follow
Agenus Inc. (NASDAQ: AGEN) will release its third quarter 2013 financial results before the market opens on October 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern...
Oct 7, 2013GSK’s Vaccine Candidate Containing Agenus’ QS-21 Stimulon® Reduces Malaria Infection in Phase 3 Trials of Over 15,000 ChildrenSignificant protection shown 18 months post vaccination
Agenus Inc. (Nasdaq: AGEN) today announced that new Phase 3 data for GlaxoSmithKline’s (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus’ QS-21 Stimulon®1 adjuvant, were...
Sep 26, 2013Agenus and Vaxlogic, LLC Execute QS-21 Stimulon® Adjuvant Licensing Agreement for Addiction, Allergy and Respiratory Vaccines
Agenus Inc. (Nasdaq: AGEN) today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon®1...
Sep 23, 2013
Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced agreement to sell $10 million of shares of its common stock, together with warrants to purchase additional shares...
Sep 19, 2013
Agenus Inc. (Nasdaq: AGEN) today announced that it received additional demand for its previously announced registered direct offering and today accepted additional commitments from existing and...